| (210) | Number of the EPO application | 17739696 |
| (220) | Filing date of the EPO application | 2017.06.12 |
| (80) | EPO patent specification publication (B) | EPB nr. 35/2020, 2020.08.26 |
| (110) | EPO patent number | 3468957 |
| (11) | Number of the document | MD 3468957 T2 |
| (21) | Number of the application | e 2019 0477 |
| (71) | Name(s) of applicant(s), code of the country | NOVARTIS AG, CH; |
| (72) | Name(s) of inventor(s), code of the country | FU Jiping, US;
JIANG Siyi, CN;
KORDIKOWSKI Andreas, CH;
SWEENEY Zachary Kevin, US; |
| (73) | Name(s) of owner(s), code of the country | NOVARTIS AG, CH; |
| (54) | Title of the invention | Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent |
| (13) | Kind-of-document code | T2 |
| (51) | International Patent Classification | C07D 261/08 (2006.01.01); A61K 31/42 (2006.01.01); A61P 31/04 (2006.01.01) |
| (19) | Country | CH |
| (41) | Date of publication of the application | 2019.05.31 |
| (49) | Date of publication of the translation of the validated European patent specification | 2020.11.30 |
| (30) | Priority | PCT/CN2016/0856, 2016.06.14, WO |
| (74) | Patent attorney | (Procedură) SOCOLOVA Sofia, Str. Drumul Viilor nr. 42, bloc 3, ap. 60, MD-2021, Chişinău, Republica Moldova |
| (86) | International application | PCT/IB2017/053468, 2017.06.12 |
| (87) | International publication | WO 2017/216705, 2017.12.21 |